BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26824432)

  • 21. Conformational control of DNA target cleavage by CRISPR-Cas9.
    Sternberg SH; LaFrance B; Kaplan M; Doudna JA
    Nature; 2015 Nov; 527(7576):110-3. PubMed ID: 26524520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems.
    Zhu LJ; Holmes BR; Aronin N; Brodsky MH
    PLoS One; 2014; 9(9):e108424. PubMed ID: 25247697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system.
    Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C
    PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Massively parallel kinetic profiling of natural and engineered CRISPR nucleases.
    Jones SK; Hawkins JA; Johnson NV; Jung C; Hu K; Rybarski JR; Chen JS; Doudna JA; Press WH; Finkelstein IJ
    Nat Biotechnol; 2021 Jan; 39(1):84-93. PubMed ID: 32895548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila.
    Gratz SJ; Ukken FP; Rubinstein CD; Thiede G; Donohue LK; Cummings AM; O'Connor-Giles KM
    Genetics; 2014 Apr; 196(4):961-71. PubMed ID: 24478335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanics of CRISPR-Cas12a and engineered variants on λ-DNA.
    Paul B; Chaubet L; Verver DE; Montoya G
    Nucleic Acids Res; 2022 May; 50(9):5208-5225. PubMed ID: 34951457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering.
    Nuñez JK; Harrington LB; Doudna JA
    ACS Chem Biol; 2016 Mar; 11(3):681-8. PubMed ID: 26857072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism.
    Liu L; Chen P; Wang M; Li X; Wang J; Yin M; Wang Y
    Mol Cell; 2017 Jan; 65(2):310-322. PubMed ID: 27989439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.
    Wang B; Zhang T; Yin J; Yu Y; Xu W; Ding J; Patel DJ; Yang H
    Mol Cell; 2021 Mar; 81(5):1100-1115.e5. PubMed ID: 33472057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a.
    Swarts DC; Jinek M
    Mol Cell; 2019 Feb; 73(3):589-600.e4. PubMed ID: 30639240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The crystal structure of Cpf1 in complex with CRISPR RNA.
    Dong D; Ren K; Qiu X; Zheng J; Guo M; Guan X; Liu H; Li N; Zhang B; Yang D; Ma C; Wang S; Wu D; Ma Y; Fan S; Wang J; Gao N; Huang Z
    Nature; 2016 Apr; 532(7600):522-6. PubMed ID: 27096363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex.
    Zeng Y; Cui Y; Zhang Y; Zhang Y; Liang M; Chen H; Lan J; Song G; Lou J
    Nucleic Acids Res; 2018 Jan; 46(1):350-361. PubMed ID: 29145633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Cas9 cleavage efficiency correlates strongly with target-sgRNA folding stability: from physical mechanism to off-target assessment.
    Xu X; Duan D; Chen SJ
    Sci Rep; 2017 Mar; 7(1):143. PubMed ID: 28273945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.